CD274 and gastroesophageal junction adenocarcinoma: On September 22, 2017, FDA approved pembrolizumab (KEYTRUDA, Merck & Co., Inc) for patients having metastatic, gastric, or gastroesophageal junction adenocarcinoma and positive for PD‐L1 expression as per an FDA‐approved test